Brooks Laboratories Ltd. | Small-cap | Healthcare
₹124.81
-4.69%
| Brooks Laboratories Stock Comparison:
Brooks Laboratories vs Sun PharmaceuticalBrooks Laboratories vs Divi's LaboratoriesBrooks Laboratories vs Innova CaptabBrooks Laboratories vs Suven Life SciencesBrooks Laboratories vs Aarti DrugsBrooks Laboratories vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 255.1M
Gross Profit 96.2M 37.71%
Operating Income 27.4M 10.72%
Net Income 95.8M 37.57%
EPS (Diluted) ₹3.25

Balance Sheet Metrics

Total Assets 1.2B
Total Liabilities 255.9M
Shareholders Equity 981.0M
Debt to Equity 0.26

Cash Flow Metrics

Revenue & Profitability Trend

Brooks Laboratories Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue i 821.9M 790.1M 624.8M 900.9M 770.4M
Cost of Goods Sold i 593.6M 610.6M 612.2M 758.0M 552.4M
Gross Profit i 228.3M 179.5M 12.6M 142.9M 218.0M
Gross Margin % i 27.8% 22.7% 2.0% 15.9% 28.3%
Operating Expenses
Research & Development i - - - - -
Selling, General & Administrative i 54.3M 46.2M 104.3M 91.0M 68.1M
Other Operating Expenses i -33.4M 148.0K 3.9M 10.8M 2.3M
Total Operating Expenses i 20.9M 46.3M 108.2M 101.8M 70.4M
Operating Income i 65.3M 14.4M -335.5M -217.0M -66.0M
Operating Margin % i 7.9% 1.8% -53.7% -24.1% -8.6%
Non-Operating Items
Interest Income i 2.3M 736.0K 921.0K 877.0K 1.7M
Interest Expense i 8.5M 7.2M 19.5M 28.3M 31.0M
Other Non-Operating Income - - - - -
Pre-tax Income i -97.9M -195.7M -383.7M -239.0M -89.9M
Income Tax i 1.8M 259.0K -73.2M -45.9M 103.8M
Effective Tax Rate % i 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income i -99.7M -195.9M -310.5M -193.1M -193.7M
Net Margin % i -12.1% -24.8% -49.7% -21.4% -25.1%
Key Metrics
EBITDA i -42.6M -170.8M -299.0M -141.7M 12.8M
EPS (Basic) i ₹-3.72 ₹-7.65 ₹-12.57 ₹-7.67 ₹-7.03
EPS (Diluted) i ₹-3.72 ₹-7.65 ₹-12.57 ₹-7.67 ₹-7.03
Basic Shares Outstanding i 26792000 25616000 24703000 25184304 24944833
Diluted Shares Outstanding i 26792000 25616000 24703000 25184304 24944833

Income Statement Trend

Brooks Laboratories Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets
Cash & Equivalents i 434.0K 1.3M 232.0K 26.0M 8.8M
Short-term Investments i 23.4M 23.3M 13.6M -2.2M -3.1M
Accounts Receivable i 199.9M 163.2M 127.5M 176.6M 137.0M
Inventory i 92.0M 96.1M 113.0M 275.2M 236.0M
Other Current Assets 22.9M 25.0K 2.0K 1.0K 291.0K
Total Current Assets i 338.8M 310.5M 276.1M 611.8M 473.6M
Non-Current Assets
Property, Plant & Equipment i 3.4M 3.3M 3.1M 74.1M 52.5M
Goodwill i 91.0K 731.0K 2.0M 6.3M 6.9M
Intangible Assets i 91.0K 731.0K 2.0M 6.3M 6.9M
Long-term Investments - - - - -
Other Non-Current Assets 14.9M - - 44.0M -
Total Non-Current Assets i 898.2M 594.0M 819.9M 1.3B 1.1B
Total Assets i 1.2B 904.5M 1.1B 2.0B 1.6B
Liabilities
Current Liabilities
Accounts Payable i 136.2M 154.4M 233.7M 280.0M 309.5M
Short-term Debt i 62.1M 52.9M 59.1M 151.2M 169.4M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 8.1M 1.0K 11.4M 1.0K 1.0K
Total Current Liabilities i 228.4M 230.5M 330.2M 488.8M 636.1M
Non-Current Liabilities
Long-term Debt i 13.7M 3.6M 6.0M 101.4M 144.4M
Deferred Tax Liabilities i - - - 0 32.3M
Other Non-Current Liabilities - - 1.0K 1.0K 1.0K
Total Non-Current Liabilities i 27.5M 18.1M 26.2M 127.1M 193.1M
Total Liabilities i 255.9M 248.6M 356.4M 615.9M 829.3M
Equity
Common Stock i 294.6M 262.5M 247.0M 247.0M 247.0M
Retained Earnings i -486.5M -386.8M -190.9M -236.2M -138.5M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 981.0M 655.9M 739.5M 1.3B 791.5M
Key Metrics
Total Debt i 75.8M 56.4M 65.1M 252.6M 313.8M
Working Capital i 110.3M 80.0M -54.2M 123.0M -162.5M

Balance Sheet Composition

Brooks Laboratories Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income i -97.9M -195.7M -383.7M -239.0M -89.9M
Depreciation & Amortization i - - - - -
Stock-Based Compensation i - - - - -
Working Capital Changes i 21.0M -39.3M -2.0M -221.8M 21.1M
Operating Cash Flow i -42.7M -234.4M -363.2M -432.9M -39.5M
Investing Activities
Capital Expenditures i -9.1M -4.4M -4.7M -203.1M -56.1M
Acquisitions i -436.6M - - 0 0
Investment Purchases i -14.7M - - -3.0M 0
Investment Sales i - - - - 3.1M
Investing Cash Flow i -460.4M -4.4M -4.7M -250.0M -53.0M
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i - - - - -
Debt Repayment i - - - - -
Financing Cash Flow i 425.0M 112.7M 176.3M 744.2M 1.0K
Free Cash Flow i 16.0M -101.2M -149.6M -606.6M -11.6M
Net Change in Cash i -78.0M -126.1M -191.6M 61.3M -92.5M

Cash Flow Trend

Brooks Laboratories Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 270.26
Forward P/E 21.86
Price to Book 3.50
Price to Sales 4.24
PEG Ratio -0.61

Profitability Ratios

Profit Margin 2.25%
Operating Margin 10.72%
Return on Equity -10.16%
Return on Assets -8.06%

Financial Health

Current Ratio 1.48
Debt to Equity 7.73
Beta 0.76

Per Share Data

EPS (TTM) ₹0.47
Book Value per Share ₹36.34
Revenue per Share ₹32.49

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
brooks 3.9B 270.26 3.50 -10.16% 2.25% 7.73
Sun Pharmaceutical 4.0T 37.84 5.44 15.08% 19.29% 3.26
Divi's Laboratories 1.7T 70.61 10.85 14.64% 23.89% 0.03
Innova Captab 47.4B 36.47 4.94 13.37% 9.98% 35.24
Suven Life Sciences 47.4B -27.66 40.25 -146.15% 84.44% 0.00
Aarti Drugs 46.1B 24.56 3.38 12.28% 7.80% 44.92

Financial data is updated regularly. All figures are in the company's reporting currency.